WS
VOR icon

Wedbush Securities’s Vor Biopharma VOR Stock Holding History

Wedbush Securities’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-500
Closed -$11K – 1192
2024
Q4 		$11K Buy
+500
New +$8.29K ﹤0.01% 1133

Other funds holding VOR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Wedbush Securities's VOR Position: Q1 2025 in Review

Wedbush Securities sold out of Vor Biopharma (VOR) in Q1 2025, closing a stake of 500 shares — an estimated $11K sold.

Wedbush Securities first reported a position in VOR in Q4 2024 and held it in 1 quarter. The position peaked at $11K in Q4 2024. 46 funds tracked by Wall St. Rank hold VOR as of Q1 2025.

  • Wedbush Securities reported no remaining Vor Biopharma position as of Q1 2025 after selling out during the quarter.
  • Wedbush Securities sold 500 Vor Biopharma shares in Q1 2025, an estimated $11K.
  • Wedbush Securities first reported a position in Vor Biopharma in Q4 2024 and held it in 1 quarter.
  • Wedbush Securities's Vor Biopharma position peaked at $11K in Q4 2024.
  • 46 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2025.

Based on Wedbush Securities's 13F filing for Q1 2025, filed 6 May 2025.